Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) Celyad Oncology (Euronext & Nasdaq: CYAD) (the "Company"), is a biotechnology company focused on innovative technologies for chimeric antigen
Regulatory News: Celyad Oncology (Euronext Nasdaq: CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced
Presentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneously Publication of results from the THINK trial, which provided proof-of-concept